Clinical Research Directory

Inclusion Criteria: Males and post-menopausal females: * With a body mass index (BMI \>25-40 kg/m2) * Having confirmed menopausal status (FSH ≥ 30 U/l) * Non-smokers (tobacco) or have quitted for over a year * Low-moderate alcohol consumption: \<7 alcoholic servings/ week * Plasma apoB ≥1.05 g/L Exclusion Criteria: * Elevated risk of cardiovascular disease (≥ 20% of calculated Framingham Risk Score) * Prior history of cardiovascular events (e.g. stroke, transient ischemic attack, myocardial infarction, angina, heart failure, arrhythmias, flutter, atrial …) * Systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg * Diabetes or HbA1c ≥ 6.5% * Reactive hypoglycaemia * Prior history of cancer within the last 3 years or if lymph nodes were removed * Thyroid disease - untreated or unstable Synthroid dose * Severe renal dysfunction - eGFR \< 30 mL/min/1.73 m² * Hepatic dysfunction - AST/ALT \> 3 times normal limit * Anemia - Hb \< 120 g/L in females and \< 130 in males * Bleeding disorders * Blood coagulation problems (i.e. bleeding predisposition) * Malabsorptive disease or surgeries (e.g. bariatric surgeries) * Autoimmune and chronic inflammatory disease (i.e. celiac, inflammatory bowel, Graves, multiple sclerosis, psoriasis, rheumatoid arthritis, and lupus). * Chronic diarrhea * Cholecystectomy (e.g. removal of gall bladder) * Sleep apnea * Seizures * Known history of difficulties accessing a vein * Known history of vagal shock or loss of consciousness during blood withdrawal * Concomitant medications (systemic corticosteroids; hypertension medication; anti-psychotic medications - psycho-active medication that promote weight gain; anticoagulant or anti-aggregates treatment (e.g. aspirin, NSAIDs, warfarin, coumadin..); systemic adrenergic agonists; weight-loss medication (e.g. GLP-1 agonists); lipid lowering medication (e.g. statins, anti-PCSK9); ) * Allergy to seafood/fish or corn oil * Allergy to bovine gelatine or glycerine (softgel components) * Allergy to Xylocaine (anesthesia used during fat tissue biopsy) * Anticipated surgery or blood transfusion * Known substance abuse * Very high physical activity (\> 5 hours of aerobic exercise per week) * Already taking more than 1 gm of EPA and/or DHA supplementation per day * Lack of compliance to the study requirements (i.e. not being fasting) * Cancellation of the same scheduled testing visit more than once * Lack of time to participate in the full length of the study (18-22 weeks) * Other conditions deemed inappropriate by the study physician (e.g. difficulties in understanding/communicating in French or English)